Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The two co-primary objectives of this study are to assess in Japanese patients with severe sepsis and/or septic shock: 1) the safety and tolerability of two different doses of intravenous AZD9773 and 2) the PK of AZD9773.
The secondary objective is to make a preliminary assessment of the pharmacodynamics of two different doses of intravenous AZD9773 in Japanese patients with severe sepsis and/or septic shock.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | AZD9773 250 units/kg (1 infusion) + 50 units/kg (9 infusions) (Dose Cohort 1): AZD9773 500 units/kg (1 infusion) + 100 units/kg (9 infusions) (Dose Cohort 2) |
|
| 2 | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AZD9773 | Drug | A single loading dose followed by 9 maintenance doses; doses to be given every 12 hours over a period of 5 days |
|
| Measure | Description | Time Frame |
|---|---|---|
| Safety and Tolerability of AZD9773 | Number of patients with treatment-emergent adverse events and number of patients who died over 28 days | 28 day study period |
| Pharmacokinetics of AZD9773 | Maximum concentration at steady state (Cmax ss) for serum total and specific fabs | From first dose to last dose (Day 5/6 or at premature treatment discontinuation) |
| Measure | Description | Time Frame |
|---|---|---|
| Pharmacodynamic Effects of AZD9773 on TNF-alpha | TNF-alpha levels over approximately 6 days following the first dose | Levels taken at baseline, over the dosing period (up to Day 5/6) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Immunocompromising comorbidities or concomitant medications:
Concomitant diseases:
Medication and allergy disqualifications.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Justin Lindemann, MD | AstraZeneca | Study Director |
| Wayne Dankner, MD | PAREXEL International Medical Services | Study Director |
| Warren Botnick, MD | PAREXEL International Medical Services | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Sapporo | Hokkaido | Japan | |||
| Research Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 23681364 | Derived | Aikawa N, Takahashi T, Fujimi S, Yokoyama T, Yoshihara K, Ikeda T, Sadamitsu D, Momozawa M, Maruyama T. A Phase II study of polyclonal anti-TNF-alpha (AZD9773) in Japanese patients with severe sepsis and/or septic shock. J Infect Chemother. 2013 Oct;19(5):931-40. doi: 10.1007/s10156-013-0612-y. Epub 2013 May 17. |
| Label | URL |
|---|---|
| D0620C00005 Study Report Synopsis | View source |
Not provided
Not provided
Subjects were screened and enrolled at six centres in Japan.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Dose Cohort 1 | AZD9773 250/50 units/kg IV |
| FG001 | Dose Cohort 2 | AZD9773 500/100 units/kg IV |
| FG002 | Placebo | Saline |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Dose Cohort 1 | AZD9773 250/50 units/kg IV |
| BG001 | Dose Cohort 2 | AZD9773 500/100 units/kg IV |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Safety and Tolerability of AZD9773 | Number of patients with treatment-emergent adverse events and number of patients who died over 28 days | Safety analysis set | Number | Participants | 28 day study period |
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Dose Cohort 1 | AZD9773 250/50 units/kg IV |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Acute Myocardial Infarction | Cardiac disorders | MedDRA 14.1 | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anaemia | Blood and lymphatic system disorders | MedDRA 14.1 | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Justin Lindemann | AstraZeneca | ClinicalTrialTransparency@astrazeneca.com |
Not provided
| ID | Term |
|---|---|
| D018805 | Sepsis |
| D012772 | Shock, Septic |
| ID | Term |
|---|---|
| D007239 | Infections |
| D018746 | Systemic Inflammatory Response Syndrome |
| D007249 | Inflammation |
| D010335 | Pathologic Processes |
Not provided
Not provided
| ID | Term |
|---|---|
| C587873 | AZD9773 |
| C513813 | CytoFab |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | Intravenous infusion of a saline solution |
|
| Kobe |
| Hyōgo |
| Japan |
| Research Site | Kumamoto | Kumamoto | Japan |
| Research Site | Osaka | Osaka | Japan |
| Research Site | Sumiyoshi-ku | Osaka | Japan |
| Research Site | Hachiōji | Tokyo | Japan |
| Research Site | Ohta-ku | Tokyo | Japan |
| redacted-CSP-D0620C00005.pdf | View source |
| BG002 |
| Placebo |
Saline |
| BG003 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
|
|
| Primary | Pharmacokinetics of AZD9773 | Maximum concentration at steady state (Cmax ss) for serum total and specific fabs | Pharmacokinetic analysis set | Geometric Mean | Full Range | ug/mL | From first dose to last dose (Day 5/6 or at premature treatment discontinuation) |
|
|
|
| Secondary | Pharmacodynamic Effects of AZD9773 on TNF-alpha | TNF-alpha levels over approximately 6 days following the first dose | Safety analysis set | Median | Full Range | pg/ml | Levels taken at baseline, over the dosing period (up to Day 5/6) |
|
|
|
| 4 |
| 7 |
| 7 |
| 7 |
| EG001 | Dose Cohort 2 | AZD9773 500/100 units/kg IV | 1 | 7 | 7 | 7 |
| EG002 | Placebo | Saline | 1 | 6 | 6 | 6 |
| Ventricular Tachycardia | Cardiac disorders | MedDRA 14.1 | Systematic Assessment |
|
| Large Intestine Perforation | Gastrointestinal disorders | MedDRA 14.1 | Systematic Assessment |
|
| Gastric Cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 14.1 | Systematic Assessment |
|
| Cerebral Infarction | Nervous system disorders | MedDRA 14.1 | Systematic Assessment |
|
| Parkinsonism | Nervous system disorders | MedDRA 14.1 | Systematic Assessment |
|
| Haemothorax | Respiratory, thoracic and mediastinal disorders | MedDRA 14.1 | Systematic Assessment |
|
| Haemorrhagic Anaemia | Blood and lymphatic system disorders | MedDRA 14.1 | Systematic Assessment |
|
| Arrhythmia | Cardiac disorders | MedDRA 14.1 | Systematic Assessment |
|
| Atrial Fibrillation | Cardiac disorders | MedDRA 14.1 | Systematic Assessment |
|
| Bradycardia | Cardiac disorders | MedDRA 14.1 | Systematic Assessment |
|
| Cardiovascular Insufficiency | Cardiac disorders | MedDRA 14.1 | Systematic Assessment |
|
| Mitral Valve Incompetence | Cardiac disorders | MedDRA 14.1 | Systematic Assessment |
|
| Sinus Tachycardia | Cardiac disorders | MedDRA 14.1 | Systematic Assessment |
|
| Supraventricular Extrasystoles | Cardiac disorders | MedDRA 14.1 | Systematic Assessment |
|
| Ventricular Extrasystoles | Cardiac disorders | MedDRA 14.1 | Systematic Assessment |
|
| Ventricular Tachycardia | Cardiac disorders | MedDRA 14.1 | Systematic Assessment |
|
| Pyloric Stenosis | Congenital, familial and genetic disorders | MedDRA 14.1 | Systematic Assessment |
|
| Adrenal Insufficiency | Endocrine disorders | MedDRA 14.1 | Systematic Assessment |
|
| Conjunctival Hyperaemia | Eye disorders | MedDRA 14.1 | Systematic Assessment |
|
| Conjunctival Oedema | Eye disorders | MedDRA 14.1 | Systematic Assessment |
|
| Abdominal Compartment Syndrome | Gastrointestinal disorders | MedDRA 14.1 | Systematic Assessment |
|
| Anal Erosion | Gastrointestinal disorders | MedDRA 14.1 | Systematic Assessment |
|
| Ascites | Gastrointestinal disorders | MedDRA 14.1 | Systematic Assessment |
|
| Cheilitis | Gastrointestinal disorders | MedDRA 14.1 | Systematic Assessment |
|
| Colitis | Gastrointestinal disorders | MedDRA 14.1 | Systematic Assessment |
|
| Constipation | Gastrointestinal disorders | MedDRA 14.1 | Systematic Assessment |
|
| Diarrhoea | Gastrointestinal disorders | MedDRA 14.1 | Systematic Assessment |
|
| Gastric Haemorrhage | Gastrointestinal disorders | MedDRA 14.1 | Systematic Assessment |
|
| Gastritis Erosive | Gastrointestinal disorders | MedDRA 14.1 | Systematic Assessment |
|
| Gastrointestinal Haemorrhage | Gastrointestinal disorders | MedDRA 14.1 | Systematic Assessment |
|
| Gastrointestinal Hypomotility | Gastrointestinal disorders | MedDRA 14.1 | Systematic Assessment |
|
| Haematochezia | Gastrointestinal disorders | MedDRA 14.1 | Systematic Assessment |
|
| Ileus Paralytic | Gastrointestinal disorders | MedDRA 14.1 | Systematic Assessment |
|
| Periodontitis | Gastrointestinal disorders | MedDRA 14.1 | Systematic Assessment |
|
| Stomatitis | Gastrointestinal disorders | MedDRA 14.1 | Systematic Assessment |
|
| Vomiting | Gastrointestinal disorders | MedDRA 14.1 | Systematic Assessment |
|
| Catheter Site Haematoma | General disorders | MedDRA 14.1 | Systematic Assessment |
|
| Device Leakage | General disorders | MedDRA 14.1 | Systematic Assessment |
|
| Disuse Syndrome | General disorders | MedDRA 14.1 | Systematic Assessment |
|
| Fat Necrosis | General disorders | MedDRA 14.1 | Systematic Assessment |
|
| Generalised Oedema | General disorders | MedDRA 14.1 | Systematic Assessment |
|
| Injection Site Erythema | General disorders | MedDRA 14.1 | Systematic Assessment |
|
| Oedema | General disorders | MedDRA 14.1 | Systematic Assessment |
|
| Oedema Peripheral | General disorders | MedDRA 14.1 | Systematic Assessment |
|
| Pain | General disorders | MedDRA 14.1 | Systematic Assessment |
|
| Cholecystitis | Hepatobiliary disorders | MedDRA 14.1 | Systematic Assessment |
|
| Hepatic Function Abnormal | Hepatobiliary disorders | MedDRA 14.1 | Systematic Assessment |
|
| Jaundice | Hepatobiliary disorders | MedDRA 14.1 | Systematic Assessment |
|
| Abdominal Abscess | Infections and infestations | MedDRA 14.1 | Systematic Assessment |
|
| Bacteraemia | Infections and infestations | MedDRA 14.1 | Systematic Assessment |
|
| Cellulitis Staphylococcal | Infections and infestations | MedDRA 14.1 | Systematic Assessment |
|
| Colostomy Infection | Infections and infestations | MedDRA 14.1 | Systematic Assessment |
|
| Fungaemia | Infections and infestations | MedDRA 14.1 | Systematic Assessment |
|
| Fungal Skin Infection | Infections and infestations | MedDRA 14.1 | Systematic Assessment |
|
| Herpes Zoster | Infections and infestations | MedDRA 14.1 | Systematic Assessment |
|
| Incision Site Cellulitis | Infections and infestations | MedDRA 14.1 | Systematic Assessment |
|
| Infectious Peritonitis | Infections and infestations | MedDRA 14.1 | Systematic Assessment |
|
| Oral Herpes | Infections and infestations | MedDRA 14.1 | Systematic Assessment |
|
| Pneumonia | Infections and infestations | MedDRA 14.1 | Systematic Assessment |
|
| Pneumonia Bacterial | Infections and infestations | MedDRA 14.1 | Systematic Assessment |
|
| Pneumonia Pneumococcal | Infections and infestations | MedDRA 14.1 | Systematic Assessment |
|
| Pneumonia Staphylococcal | Infections and infestations | MedDRA 14.1 | Systematic Assessment |
|
| Postoperative Wound Infection | Infections and infestations | MedDRA 14.1 | Systematic Assessment |
|
| Pseudomembranous Colitis | Infections and infestations | MedDRA 14.1 | Systematic Assessment |
|
| Septic Shock | Infections and infestations | MedDRA 14.1 | Systematic Assessment |
|
| Tinea Cruris | Infections and infestations | MedDRA 14.1 | Systematic Assessment |
|
| Tracheostomy Infection | Infections and infestations | MedDRA 14.1 | Systematic Assessment |
|
| Urinary Tract Infection | Infections and infestations | MedDRA 14.1 | Systematic Assessment |
|
| Gastrointestinal Anastomotic Leak | Injury, poisoning and procedural complications | MedDRA 14.1 | Systematic Assessment |
|
| Incision Site Haemorrhage | Injury, poisoning and procedural complications | MedDRA 14.1 | Systematic Assessment |
|
| Post Procedural Complication | Injury, poisoning and procedural complications | MedDRA 14.1 | Systematic Assessment |
|
| Post Procedural Haemorrhage | Injury, poisoning and procedural complications | MedDRA 14.1 | Systematic Assessment |
|
| Tracheal Obstruction | Injury, poisoning and procedural complications | MedDRA 14.1 | Systematic Assessment |
|
| Traumatic Lung Injury | Injury, poisoning and procedural complications | MedDRA 14.1 | Systematic Assessment |
|
| Wound Complication | Injury, poisoning and procedural complications | MedDRA 14.1 | Systematic Assessment |
|
| Blood Creatine Phosphokinase Increased | Investigations | MedDRA 14.1 | Systematic Assessment |
|
| Blood Pressure Decreased | Investigations | MedDRA 14.1 | Systematic Assessment |
|
| Body Temperature Increased | Investigations | MedDRA 14.1 | Systematic Assessment |
|
| C-Reactive Protein Increased | Investigations | MedDRA 14.1 | Systematic Assessment |
|
| Heart Rate Increased | Investigations | MedDRA 14.1 | Systematic Assessment |
|
| Hepatic Enzyme Increased | Investigations | MedDRA 14.1 | Systematic Assessment |
|
| Pancreatic Enzymes Increased | Investigations | MedDRA 14.1 | Systematic Assessment |
|
| Urine Output Decreased | Investigations | MedDRA 14.1 | Systematic Assessment |
|
| White Blood Cell Count Decreased | Investigations | MedDRA 14.1 | Systematic Assessment |
|
| Acidosis | Metabolism and nutrition disorders | MedDRA 14.1 | Systematic Assessment |
|
| Gout | Metabolism and nutrition disorders | MedDRA 14.1 | Systematic Assessment |
|
| Hyperglycaemia | Metabolism and nutrition disorders | MedDRA 14.1 | Systematic Assessment |
|
| Hyperkalaemia | Metabolism and nutrition disorders | MedDRA 14.1 | Systematic Assessment |
|
| Hypoalbuminaemia | Metabolism and nutrition disorders | MedDRA 14.1 | Systematic Assessment |
|
| Hypokalaemia | Metabolism and nutrition disorders | MedDRA 14.1 | Systematic Assessment |
|
| Hyponatraemia | Metabolism and nutrition disorders | MedDRA 14.1 | Systematic Assessment |
|
| Hypovolaemia | Metabolism and nutrition disorders | MedDRA 14.1 | Systematic Assessment |
|
| Metabolic Alkalosis | Metabolism and nutrition disorders | MedDRA 14.1 | Systematic Assessment |
|
| Muscular Weakness | Musculoskeletal and connective tissue disorders | MedDRA 14.1 | Systematic Assessment |
|
| Gastric Cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 14.1 | Systematic Assessment |
|
| Delirium | Psychiatric disorders | MedDRA 14.1 | Systematic Assessment |
|
| Insomnia | Psychiatric disorders | MedDRA 14.1 | Systematic Assessment |
|
| Mental Disorder Due To A General Medical Condition | Psychiatric disorders | MedDRA 14.1 | Systematic Assessment |
|
| Renal Impairment | Renal and urinary disorders | MedDRA 14.1 | Systematic Assessment |
|
| Atelectasis | Respiratory, thoracic and mediastinal disorders | MedDRA 14.1 | Systematic Assessment |
|
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | MedDRA 14.1 | Systematic Assessment |
|
| Haemoptysis | Respiratory, thoracic and mediastinal disorders | MedDRA 14.1 | Systematic Assessment |
|
| Oropharyngeal Pain | Respiratory, thoracic and mediastinal disorders | MedDRA 14.1 | Systematic Assessment |
|
| Pleural Effusion | Respiratory, thoracic and mediastinal disorders | MedDRA 14.1 | Systematic Assessment |
|
| Pneumomediastinum | Respiratory, thoracic and mediastinal disorders | MedDRA 14.1 | Systematic Assessment |
|
| Pneumonia Aspiration | Respiratory, thoracic and mediastinal disorders | MedDRA 14.1 | Systematic Assessment |
|
| Pneumothorax | Respiratory, thoracic and mediastinal disorders | MedDRA 14.1 | Systematic Assessment |
|
| Productive Cough | Respiratory, thoracic and mediastinal disorders | MedDRA 14.1 | Systematic Assessment |
|
| Pulmonary Congestion | Respiratory, thoracic and mediastinal disorders | MedDRA 14.1 | Systematic Assessment |
|
| Pulmonary Fibrosis | Respiratory, thoracic and mediastinal disorders | MedDRA 14.1 | Systematic Assessment |
|
| Tachypnoea | Respiratory, thoracic and mediastinal disorders | MedDRA 14.1 | Systematic Assessment |
|
| Tracheal Oedema | Respiratory, thoracic and mediastinal disorders | MedDRA 14.1 | Systematic Assessment |
|
| Vocal Cord Polyp | Respiratory, thoracic and mediastinal disorders | MedDRA 14.1 | Systematic Assessment |
|
| Wheezing | Respiratory, thoracic and mediastinal disorders | MedDRA 14.1 | Systematic Assessment |
|
| Decubitus Ulcer | Skin and subcutaneous tissue disorders | MedDRA 14.1 | Systematic Assessment |
|
| Dermatitis | Skin and subcutaneous tissue disorders | MedDRA 14.1 | Systematic Assessment |
|
| Dermatitis Contact | Skin and subcutaneous tissue disorders | MedDRA 14.1 | Systematic Assessment |
|
| Dry Skin | Skin and subcutaneous tissue disorders | MedDRA 14.1 | Systematic Assessment |
|
| Erythema | Skin and subcutaneous tissue disorders | MedDRA 14.1 | Systematic Assessment |
|
| Petechiae | Skin and subcutaneous tissue disorders | MedDRA 14.1 | Systematic Assessment |
|
| Purpura | Skin and subcutaneous tissue disorders | MedDRA 14.1 | Systematic Assessment |
|
| Rash | Skin and subcutaneous tissue disorders | MedDRA 14.1 | Systematic Assessment |
|
| Skin Erosion | Skin and subcutaneous tissue disorders | MedDRA 14.1 | Systematic Assessment |
|
| Skin Exfoliation | Skin and subcutaneous tissue disorders | MedDRA 14.1 | Systematic Assessment |
|
| Skin Haemorrhage | Skin and subcutaneous tissue disorders | MedDRA 14.1 | Systematic Assessment |
|
| Skin Oedema | Skin and subcutaneous tissue disorders | MedDRA 14.1 | Systematic Assessment |
|
| Subcutaneous Emphysema | Skin and subcutaneous tissue disorders | MedDRA 14.1 | Systematic Assessment |
|
| Vascular Purpura | Skin and subcutaneous tissue disorders | MedDRA 14.1 | Systematic Assessment |
|
| Dermabrasion | Surgical and medical procedures | MedDRA 14.1 | Systematic Assessment |
|
| Flushing | Vascular disorders | MedDRA 14.1 | Systematic Assessment |
|
| Hypertension | Vascular disorders | MedDRA 14.1 | Systematic Assessment |
|
| Jugular Vein Thrombosis | Vascular disorders | MedDRA 14.1 | Systematic Assessment |
|
Not provided
| D013568 |
| Pathological Conditions, Signs and Symptoms |
| D012769 | Shock |
|
| TNF-alpha level on Day 6 (pre-morning dose) |
|